Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 5:33 AM ET

Pharmaceuticals

Company Overview of Tioga Pharmaceuticals, Inc.

Company Overview

Tioga Pharmaceuticals, Inc. develops therapies for the treatment of pruritus in atopic dermatitis. It also offers therapies to treat pruritus associated with various other conditions, including psoriasis, end-stage renal disease, liver diseases (cholestatic disease and primary biliary cirrhosis), and hyperthyroidism. The company was founded in 2005 and is based in San Diego, California.

4747 Executive Drive

Suite 700

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-677-6077

Fax:

858-452-8799

Key Executives for Tioga Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 54
Chief Operating Officer
Chief Medical Officer
Chief Medical Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Tioga Pharmaceuticals, Inc. Key Developments

Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis

Tioga Pharmaceuticals announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States. Because of its mechanism of action, asimadoline has the potential to treat pruritus associated with a variety of conditions, including atopic dermatitis, psoriasis, end-stage renal disease, liver diseases such as cholestatic disease and primary biliary cirrhosis, malignancies, adverse drug effects, and certain orphan diseases. Chronic pruritus, which is defined as pruritus lasting six weeks or more, is associated with significant decrease in quality of life, including impact on sleep, anxiety, depression, and ability to work and lacks effective treatment options. Chronic pruritus is estimated to occur in approximately 20% of the general population (lifetime prevalence), with a very high incidence in certain dermatological and systemic conditions. The kappa-opioid system plays a pivotal role in the sensory transmission and processing of itch sensation from the skin to the brain. Animal models of chronic pruritus have demonstrated decreased kappa-opioid receptor activation or down regulation, coupled with increased mu-opioid receptor activation. Asimadoline has demonstrated efficacy in animal models of pruritus by significantly reducing the frequency of scratching induced by intra-dermally injected Substance P and significantly inhibiting scratching behavior induced by intra-dermally injected histamine or dinitrofluorobenzene.

Tioga Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Tioga Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Similar Private Companies By Industry

Company Name Region
Tacurion Pharma, Inc. United States
Satiogen Pharmaceuticals, Inc. United States
Quanticel Pharmaceuticals, Inc. United States
Boiron-Borneman, Inc. United States
HMGene, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tioga Pharmaceuticals, Inc., please visit www.tiogapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.